Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026

manilatimes.net · 2026-09-07

COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondroplasia aged 0 to 'Ascendis is building leadership with its growing portfolio of treatments for people living with hypoparathyroidism and growth disorders, which we look forward to showcasing at ESPE 2026,” said Aimee Shu, M.D., Executive Vice President, Chief Medical Officer at Ascendis Pharma. 'We are especially excited to share these early data from our trial of TransCon CNP in infants with achondroplasia. We believe early medical intervention with TransCon CNP in these youngest children may help mitigate the neuromusculoskeletal complications and co-morbidities associated with this condition.”

TickrTrends take: Ascendis Pharma operates in a sector where clinical data presentations can materially influence investor perception of pipeline value, particularly for rare disease programs where successful trial results may support premium valuations. TickrTrends is currently awaiting full valuation metrics for ASND, meaning the market has not yet settled on a clear consensus regarding the company's worth. Upcoming endocrinology data disclosures at major conferences represent the type of clinical milestones that typically drive valuation reassessment, so investors monitoring ASND should track whether these presentations move the needle on pipeline confidence and addressable market sizing.

Read the full story at manilatimes.net →